Atyr PHARMA INC (NASDAQ:ATYR - Get Free Report) saw unusually-strong trading volume on Tuesday . Approximately 4,293,116 shares traded hands during mid-day trading, an increase of 343% from the previous session's volume of 969,901 shares.The stock last traded at $5.68 and had previously closed at $4.75.
Analyst Ratings Changes
Several brokerages recently issued reports on ATYR. HC Wainwright reiterated a "buy" rating and set a $35.00 price target on shares of Atyr PHARMA in a research report on Wednesday. Leerink Partnrs raised Atyr PHARMA to a "strong-buy" rating in a research report on Tuesday, February 18th. Finally, Leerink Partners initiated coverage on Atyr PHARMA in a report on Tuesday, February 18th. They set an "outperform" rating and a $16.00 target price on the stock. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Atyr PHARMA presently has a consensus rating of "Buy" and a consensus price target of $18.60.
View Our Latest Research Report on Atyr PHARMA
Atyr PHARMA Trading Up 0.6%
The stock's fifty day simple moving average is $3.49 and its two-hundred day simple moving average is $3.52. The firm has a market cap of $478.84 million, a PE ratio of -5.72 and a beta of 0.88. The company has a quick ratio of 5.41, a current ratio of 5.41 and a debt-to-equity ratio of 0.02.
Atyr PHARMA (NASDAQ:ATYR - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.17) earnings per share for the quarter, beating analysts' consensus estimates of ($0.19) by $0.02. On average, sell-side analysts forecast that Atyr PHARMA INC will post -0.91 EPS for the current fiscal year.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently made changes to their positions in the company. D.A. Davidson & CO. bought a new stake in Atyr PHARMA in the 4th quarter worth about $141,000. Charles Schwab Investment Management Inc. purchased a new stake in shares of Atyr PHARMA during the 4th quarter valued at about $144,000. Victory Capital Management Inc. bought a new stake in shares of Atyr PHARMA in the fourth quarter worth approximately $37,000. Raymond James Financial Inc. bought a new stake in shares of Atyr PHARMA in the fourth quarter worth approximately $39,000. Finally, Farther Finance Advisors LLC purchased a new position in shares of Atyr PHARMA during the fourth quarter valued at approximately $88,000. Institutional investors own 61.72% of the company's stock.
About Atyr PHARMA
(
Get Free Report)
aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
Featured Stories
Before you consider aTyr Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and aTyr Pharma wasn't on the list.
While aTyr Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
